PF-07284892

Other Medications

1 Clinical Trials

Description

PF-07284892 is an investigational drug, meaning it is still being studied in clinical trials and is not yet approved for use in patients. It was being evaluated by Pfizer in a Phase 1 clinical trial (NCT04800822) for advanced solid tumors, including colorectal cancer. This trial aimed to determine the safest dose and see how the drug affects the body (pharmacokinetics) and if it has any early signs of effectiveness (preliminary clinical activity). The trial also looked at PF-07284892 in combination with other drugs (lorlatinib, encorafenib, cetuximab, or binimetinib). The trial has been terminated. The study included patients with specific genetic changes (mutations) in their tumors, such as ALK, BRAF (V600E), or ROS1 mutations. Because the trial has been terminated, it is unlikely that PF-07284892 will continue development for colorectal cancer.

Mechanism of Action

PF-07284892 is being studied as a potential treatment for certain types of cancer. The specific way it works (its mechanism of action) is being investigated in clinical trials. It is designed to target specific proteins involved in tumor growth and survival, particularly in tumors with certain genetic mutations like ALK, BRAF (V600E), or ROS1.

Side Effects

As PF-07284892 is an investigational drug and the clinical trial has been terminated Specific side effect data is limited. In Phase 1 trials The primary focus is on safety So researchers carefully monitor patients for any adverse events. Common side effects observed in early-phase cancer drug trials can vary widely depending on the drug's mechanism and dose But can include fatigue Nausea Diarrhea Skin reactions And changes in blood counts. More specific side effect information would come from the completed trial data But is not typically released publicly for terminated trials.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT04800822 Phase 1
Terminated
PF-07284892 in Participants With Advanced Solid Tumors
United States

Quick Info

CategoryOther Medications
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
771 trials
Leucovorin
Other Medications
631 trials
Trifluridine
Other Medications
45 trials
Paclitaxel
Other Medications
43 trials
Cyclophosphamid
Other Medications
40 trials
Cyclophosphamide
Other Medications
39 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.